Cited 44 times in
CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 성진실 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 금웅섭 | - |
dc.contributor.author | 김용배 | - |
dc.date.accessioned | 2015-04-24T16:27:40Z | - |
dc.date.available | 2015-04-24T16:27:40Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103554 | - |
dc.description.abstract | PURPOSE: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. METHODS AND MATERIALS: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. RESULTS: Seventeen patients (25%) had a 50% or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline <or=40% (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. CONCLUSIONS: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline <or=40% may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1148~1154 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Analysis of Variance | - |
dc.subject.MESH | CA-19-9 Antigen/blood* | - |
dc.subject.MESH | Combined Modality Therapy/methods | - |
dc.subject.MESH | Dose-Response Relationship, Radiation | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pancreatic Neoplasms/blood* | - |
dc.subject.MESH | Pancreatic Neoplasms/drug therapy | - |
dc.subject.MESH | Pancreatic Neoplasms/mortality | - |
dc.subject.MESH | Pancreatic Neoplasms/radiotherapy | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.title | CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | WOONG SUB KOOM | - |
dc.contributor.googleauthor | JINSIL SEONG | - |
dc.contributor.googleauthor | YONG BAE KIM | - |
dc.contributor.googleauthor | HAE OK PYUN | - |
dc.contributor.googleauthor | SI YOUNG SONG | - |
dc.identifier.doi | 10.1016/j.ijrobp.2008.06.1483 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A00273 | - |
dc.contributor.localId | A00744 | - |
dc.relation.journalcode | J01157 | - |
dc.identifier.eissn | 1879-355X | - |
dc.identifier.pmid | 18760544 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0360301608024620 | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.subject.keyword | CA 19-9 | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Tumor response | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Koom, Woong Sub | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Koom, Woong Sub | - |
dc.contributor.affiliatedAuthor | Kim, Yong Bae | - |
dc.citation.volume | 73 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1148 | - |
dc.citation.endPage | 1154 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.73(4) : 1148-1154, 2009 | - |
dc.identifier.rimsid | 37922 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.